| Document |
Document Title |
|
WO/2014/201111A1 |
Embodiments disclosed herein provide compositions and methods for treating cancer having deregulated mTOR signaling or mTOR hyperactivity, e.g., lymphangioleiomyomatosis (LAM), LAM/TSC or treating and/or management of tuberous sclerosis ...
|
|
WO/2014/195961A1 |
The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods ...
|
|
WO/2014/191426A1 |
A method for the purification and preparation of melphalan that allows to obtain melphalan with purity higher than 99.5% is described.
|
|
WO/2014/194268A1 |
Various embodiments of the present invention are directed to switchable carboxybetaine-based polymers, hydrogels, and/or elastomers, along with novel related monomers, crosslinkers, and methods. Under acidic conditions, the materials und...
|
|
WO/2014/189646A1 |
The present invention relates to novel optically active salts of 2-aminoalkanoic acid and acid ester derivatives and processes for making such derivatives that are ideal for the preparation of therapeutically useful cysteine protease inh...
|
|
WO/2014/188783A1 |
The purpose of the invention is to provide a production method that makes possible the industrial production of an optically active α-amino acid at high yield and high enantioselectivity, to provide a simple method for producing optical...
|
|
WO/2014/180175A1 |
The present invention relates to a method for synthesising 5-aminolevulinic acid, comprising the following four steps: (1) a ring-opening reaction, (2) synthesis of N-substituted phthalimide, (3) an oxidation reaction, and (4) a hydrolys...
|
|
WO/2014/175267A1 |
The purpose of the invention is to provide a novel organometallic compound that can be utilized as a catalyst having high generality, high activity, and excellent functional group selectivity. The invention pertains to a novel organometa...
|
|
WO/2014/168912A1 |
Antimicrobial compounds are provided that are polymerizable. The compounds include monomers with antimicrobial properties. The compounds have cross-linking properties and are hydrolytically stable. The compounds may be utilized in dental...
|
|
WO/2014/155291A1 |
The invention provides processes for the manufacture of a compound of formula (IA ). The invention further provides improved methods for the conversion of the compound of formula (I A ) into pregabalin.
|
|
WO/2014/152494A1 |
The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
|
|
WO/2014/152431A1 |
Provided herein are stabilized radioiodinated and astatinated compounds, and to methods for their preparation.
|
|
WO/2014/150909A1 |
This invention relates to lysine isotopologues of Formulas I and l-A, as described herein, and processes for synthesizing the same and derivatives and intermediates involved therein. In one aspect, described herein is a chemical compound...
|
|
WO/2014/142748A1 |
The invention relates to compounds for use as quorum sensing inhibitors, and in particular, to quorum sensing inhibitors of Pseudomonas aeruginosa.
|
|
WO/2014/139161A1 |
One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs...
|
|
WO/2014/135403A1 |
The present invention is directed towards a process for working up a reaction mixture selected from aqueous solutions and aqueous slurries, said reaction mixture containing at least one compound (C) selected from methylglycine diacetate,...
|
|
WO/2014/133017A1 |
Provided is a mononuclear iron complex that comprises an iron-silicon bond that is represented by formula (1) and that exhibits excellent catalyst activity in each of a hydrosilylation reaction, a hydrogenation reaction, and reduction of...
|
|
WO/2014/130992A1 |
Screening assays and methods of using same for screening to identify modulator agents or compounds that target endoplasmic reticulum stress related signaling pathways to induce apoptosis are described herein. Pharmaceutical compositions ...
|
|
WO/2014/125145A1 |
The invention relates to a novel method for modifying hydroxylated cyclic amino acids, especially 4-hydroxyproline, which is a commercial, relatively cheap, natural amino acid, in order to provide other amino acids of high optical purity...
|
|
WO/2014/126071A1 |
A compound having the structure represented by general formula (I) (therein, n is either 0 or 1; R1 represents a hydrogen atom (only in cases where n=0), a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, an optionally substit...
|
|
WO/2014/126244A1 |
Disclosed are a method for producing an amino acid and an amino acid synthesis kit that can efficiently and in an extremely short period of time synthesize a desired amino acid at a high stereoselectivity regardless of the presence/absen...
|
|
WO/2014/123485A1 |
A method for the purification of a desired protein from a protein preparation includes conditioning the protein preparation by treatment with soluble organic multivalent ions, immobilized organic multivalent ions, or both, optionally in ...
|
|
WO/2014/124234A1 |
The present invention relates to alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/122184A1 |
Herein described are deuterated catecholamine derivatives of the general Formula (I) wherein R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichm...
|
|
WO/2014/119731A1 |
Provided is a method for producing D-alloisoleucine in a fewer steps and with high yield by an asymmetric transformation reaction of L-isoleucine. A method for producing D-alloisoleucine, involving a step of allowing a tartaric acid deri...
|
|
WO/2014/108564A1 |
The subject matter of the present invention is the novel molecules of formulae E, E' and F. These molecules prove to be synthesis intermediates that are very advantageous for the manufacture of derivatives of sphingosine or of ceramides ...
|
|
WO/2014/106616A1 |
The invention concerns a method for the racemisation of la L-lysine that can be used to continuously obtain an aqueous solution containing 30-35% by weight of D, L-lysine. The method involves mixing an L-lysine powder in glacial acetic a...
|
|
WO/2014/095739A1 |
The invention relates to precursors for the production of optically active 18F-labelled amino acids bearing the radiochemical label on an aromatic ring, in particular 6-[18F]Fluoro-3,4- dihydroxy-L-phenylalanine ([18F]-L-DOPA) as well as...
|
|
WO/2014/098063A1 |
The present invention addresses the problem of providing: a production method capable of high-yield/high-enantioselectively producing an optically active amino acid having few restrictions on the material that can be used as the substrat...
|
|
WO/2014/096155A1 |
The present invention relates to L-glutamate-derived compounds of general formula (I) in which the R radical is a linear or branched C5 to C2 alkyl group, • - or the benzyl radical, • - or the phenethyl radical, for topical use as a ...
|
|
WO/2014/098046A1 |
A method for producing a compound represented by formula (2) or a salt thereof, characterized in that a compound represented by formula (1) or a salt thereof is reacted with 2,2-dialkoxypropane or isopropenyl alkyl ether in the presence ...
|
|
WO/2014/090943A1 |
The invention relates to a salt of glutamic acid-N,N-diacetic acid (GLDA) of the formula GLDA-YmHn, wherein m is equal to or more than 0.5 and lower than or equal to 2.5, n +m = 4, and wherein Y is a monovalent cation that is not a proto...
|
|
WO/2014/090942A1 |
The invention relates to glutamic acid N,N-diacetic acid (GLDA) of the formula GLDA-YmHn, wherein m is less than 0.5, n +m = 4, Y is a monovalent cation that is not a proton, in the form of crystals, a process to make these crystals,and ...
|
|
WO/2014/087416A1 |
The present invention provided amphoteric detergent compatible amphoteric softeners based on alkyl ammonium backbone of formula 1, 2 or 3. These softeners may be used directly to impart softness to the substrates such as fabrics. The inv...
|
|
WO/2014/082046A1 |
The present invention relates to trisodium diethylenetriamine pentaacetic acid (DTPA) di-ethyl esters. The invention further relates to compositions comprising DTPA di-ethyl esters and methods of using the same.
|
|
WO/2014/080051A1 |
The invention relates to the use of L-carnitine or its salts and derivatives in dermatological cosmetic products, preferably within the technical field associated with the cosmetic treatment of all types of superficial scars and stretch ...
|
|
WO/2014/081756A1 |
Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
|
|
WO/2014/078669A1 |
The invention generally relates to compounds having structure (I) wherein x represents alkyl, aryl or het-aryl, each of y independently represents hydrogen or halogen and z represents hydrogen or alkyl. Further, said compounds are inhibi...
|
|
WO/2014/068333A2 |
There is provided a process for the preparation of Lacosamide in a particular polymorphic form, which process involves the isolation of a salt of formula I : according to the methods defined in the application.
|
|
WO/2014/069555A1 |
Provided is a compound that exhibits an excellent melanogenesis-inhibiting effect (skin-lightening effect), exhibits an excellent antimicrobial effect, excels in terms of temporal stability and the like, and is suitable for use as an ing...
|
|
WO/2014/070268A2 |
A method of preparing a lubricating oil additive composition comprising reacting (A) a nitrogen-containing reactant derived from reacting a first reaction product with a triglyceride, wherein the first reaction product is derived by reac...
|
|
WO/2014/071038A1 |
The invention relates to a class of novel surfactants that have utility in the recovery and/or extraction of oil.
|
|
WO/2014/066713A1 |
A process has been developed for preparing 2-methoxymethyl-1,4-benzenediamine (IV-a), other compounds of formula (IV), and the salts thereof, all of which may be used as primary intermediates in compositions for dyeing keratin fibers.
|
|
WO/2014/064077A1 |
The present invention relates to a new crystalline phase of (3S,3S') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) (ABSD) with L-lysine and its use, particularly in the pharmaceutical industry, and to processes for preparation the...
|
|
WO/2014/061508A1 |
Provided are: a novel chiral 4-boronophenylalanine (BPA) derivative; a method for producing the derivative; and a method for producing 18F-2-fluoro-4-borono-L-phenylalanine (18F-labeled BPA; 18F-BPA) using the derivative. A compound repr...
|
|
WO/2014/059928A1 |
A compound having formula (I) or formula (II) for use in anticancer or anti-obesity.
|
|
WO/2014/056464A1 |
The present solution relates to an improved production method of elvitegravir of formula I, which is being clinically evaluated for treatment of HIV infection. Elvitegravir of formula I is produced via the intermediate of formula II, the...
|
|
WO/2014/054391A1 |
A compound represented by general formula (1). In general formula (1), R1 represents either one of a protective group for a hydroxy group and a hydrogen atom, and R2 and R3 independently represent a protective group for an amino group.
|
|
WO/2014/052087A1 |
A chelating agent, a metal-chelate, and a contrast agent are provided, wherein the chelating agent comprises a compound of structure (I), wherein R1 R2,R3,R8,R7,R'7 R'1,R'2,R'3 and R8' are selected from a hydrogen, a protected C1-C3 hydr...
|
|
WO/2014/048313A1 |
Disclosed are a compound as represented by formula (I), which is a condensation product of a theanine derivative and a carboxylic acid coumarin derivative, a compound as represented by formula (II), which is an intermediate of the conden...
|
